Archive · 23 Jul 2025
Dr. Reddy's Q1 FY26 Profit Up 1% Despite North America Challenges
Dr. Reddy's, a drug company, made slightly more money this past quarter compared to last year.
Although they sold more stuff overall, the profits didn't go up much because they had to lower the price of some key medicines in America.
They also did well in Europe and other countries, launching new products.
The company is dealing with inspections from the US government, which they are addressing, and they are keeping an eye on how new rules might affect their business in the future.
Dr. Reddy's Q1 FY26 net profit saw a 1% increase, reaching ₹1,409 crore.
Revenue increased 11% to ₹8,545 crore, driven by growth in Europe, India, and emerging markets.
Price erosion in North America, particularly for Lenalidomide, impacted profitability.
The company launched five new products in the US and five new brands in the domestic Indian market.
Dr. Reddy's received observations from the USFDA at two facilities; responses were submitted within timelines.
- Who
- Dr. Reddy's Laboratories
- What
- Dr. Reddy's Laboratories' financial performance in Q1 FY26.
- When
- The first quarter that ended June 30, 2025
- Where
- Hyderabad-based company operating globally, with a focus on North America, Europe, and India.
- Why
- Driven by factors including price erosion in North America and growth in other markets.
Dr. Reddy's Performance
Market Performance
Performance of Company
Dr. Reddy's Performance
Increased revenue across all markets.
Market Performance
Impact of Price erosion in North America on company profits.
- Net Profit
- ₹1,409 crore
- Revenue
- ₹8,545 crore
- Revenue Growth
- 11%
- North America Revenue Decline
- 11%
- Europe Revenue Growth
- 140%
- Indian Business Growth
- 11%
- Net Cash Surplus
- ₹2,922 crore